Opioid Drug News and Research

RSS

Exparel (DepoBupivacaine) shows promise in hernia repair

A Phase II trial of a single intraoperative administration of Exparel (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment.

14 Dec 2008

Decline in teen marijuana use stalls - trends in cigarette and alcohol use continues to fall

There are signs that the ongoing decline in teen marijuana use in recent years has stalled; however the downward trend in cigarette and alcohol use continues, according to the 2008 Monitoring the Future (MTF) Survey. Results were announced today at a news conference.

11 Dec 2008

Sugar is addictive

A Princeton University scientist will present new evidence today demonstrating that sugar can be an addictive substance, wielding its power over the brains of lab animals in a manner similar to many drugs of abuse.

10 Dec 2008

AcelRx Pharmaceuticals reports positive results in trial of sublingual Sufentanil NanoTabs in treating post-op pain

AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.

10 Dec 2008

King Pharmaceuticals and Alpharma sign definitive merger agreement

King Pharmaceuticals, Inc. and Alpharma Inc. have announced that the two companies have signed a definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity value of approximately $1.6 billion.

24 Nov 2008

Tapentadol hydrochloride approved for pain relief

The U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain.

24 Nov 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

Researchers examine trends in prescription opioid use for non-cancer pain

A review of more than 4 million insured patients with private coverage and Medicaid, published in the The Journal of Pain showed that rates of opioid use did not differ widely between non-cancer pain conditions but there were higher rates of opioid use among Medicaid patients.

18 Nov 2008

Women separated from abusive partners often experience high-disability chronic pain after two years

Despite ample evidence that chronic pain is a serious problem in women with a history of abuse, little is known about the severity and patterns of chronic pain in this population.

18 Nov 2008

Pain and itch regulated by different molecular mechanisms

Historically, scientists have regarded itching as a less intense version of the body's response to pain, but researchers at Washington University School of Medicine in St. Louis have determined that pain and itch actually are regulated by different molecular mechanisms.

17 Nov 2008

CAPHOSOL shown to benefit cancer patients undergoing chemotherapy and radiation therapy

New data show that CAPHOSOL, an advanced electrolyte solution, results in low rates of oral mucositis and pain in patients with head and neck (HN) cancer who are undergoing chemotherapy and radiation therapy.

17 Nov 2008

TheraQuest's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA

TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.

13 Nov 2008

Extended suboxone treatment substantially improves outcomes for opioid-addicted young adults

In the first clinical trial of a medication that was used for an extended time to treat opioid addiction in young adults, participants who received counseling and Suboxone (buprenorphine-naloxone) for 12 weeks had substantially better outcomes than those who received the standard treatment of short-term detoxification and counseling.

4 Nov 2008

Titan Pharmaceuticals updates on Probuphine patent application

Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company's method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain.

31 Oct 2008

Teva granted FDA approval for Fentanyl transdermal system

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil's chronic pain treatment Duragesic. Shipment of this product has commenced.

20 Oct 2008

Three million HIV positive injecting drug users

New research suggests there could be three million injecting drug users (IDUs) worldwide who are HIV positive; and that the number of countries reporting injecting drug use has increased over the last decade.

23 Sep 2008

Naltrexone-derived pyridomorphinan shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry.

11 Sep 2008

Over 10 million Americans are taking opioids

Researchers from Boston University's Slone Epidemiology Center have found that in a given week, over 10 million Americans are taking opioids, and more than 4 million are taking them regularly (at least five days per week, for at least four weeks). These findings appear in the August 31 issue of the journal Pain.

27 Aug 2008

Watson Pharmaceuticals announces limited recall of Fentanyl transdermal patches

Watson Pharmaceuticals, Inc. has announced that one lot of 75 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

10 Aug 2008

Methadone shows promise against leukemia

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

3 Aug 2008